dc.contributor.author | Firooz, AR | |
dc.contributor.author | Fouladi, DF | |
dc.date.accessioned | 2018-08-26T09:01:29Z | |
dc.date.available | 2018-08-26T09:01:29Z | |
dc.date.issued | 2013 | |
dc.identifier.uri | http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/55009 | |
dc.description.abstract | Alopecia areata is a chronic disease that may respond poorly to treatment. This study aimed to examine the efficacy of methotrexate plus prednisolone in severe alopecia areata. A total of 10 patients with long-lasting extensive alopecia areata were studied. These patients were recruited from two private dermatological clinics in Tehran (Iran) from September 2011 through December 2012. Oral prednisolone (initial: 0.5 mg kg day-1) and oral methotrexate (5-10 mg week-1) were administered and tapered when a full hair regrowth was achieved. A total regrowth of the terminal hair was regarded "success". Descriptive analysis was used in this study. Success was achieved in 80% of the patients. Within a mean follow-up of 14.40 months after treatment, relapse occurred in 4 patients (patchy loss = 2, patchy and succeeding diffuse loss = 1, diffuse loss = 1). Relapse resolved using local corticosteroid/dose increase in all 4 patients. Complications were minor and resolved spontaneously. This study showed that oral methotrexate plus oral prednisolone is effective and safe in severe alopecia areata. © 2013 Academic Journals Inc. | |
dc.language.iso | English | |
dc.relation.ispartof | American Journal of Drug Discovery and Development | |
dc.subject | methotrexate | |
dc.subject | prednisolone | |
dc.subject | acne | |
dc.subject | adult | |
dc.subject | alopecia areata | |
dc.subject | amenorrhea | |
dc.subject | anemia | |
dc.subject | article | |
dc.subject | body weight disorder | |
dc.subject | case study | |
dc.subject | clinical article | |
dc.subject | controlled study | |
dc.subject | disease duration | |
dc.subject | disease severity | |
dc.subject | drug efficacy | |
dc.subject | drug safety | |
dc.subject | drug tolerability | |
dc.subject | female | |
dc.subject | hair growth | |
dc.subject | hair loss | |
dc.subject | herpes simplex | |
dc.subject | human | |
dc.subject | hypertension | |
dc.subject | Iran | |
dc.subject | male | |
dc.subject | muscle cramp | |
dc.subject | patient compliance | |
dc.subject | prospective study | |
dc.subject | treatment outcome | |
dc.subject | treatment response | |
dc.title | Methotrexate plus prednisolone in severe alopecia areata | |
dc.type | Article | |
dc.citation.volume | 3 | |
dc.citation.issue | 3 | |
dc.citation.spage | 188 | |
dc.citation.epage | 193 | |
dc.citation.index | Scopus | |
dc.identifier.DOI | https://doi.org/10.3923/ajdd.2013.188.193 | |